smooth muscle cell proliferation and migration has been a long-standing goal in vascular biology and medicine. In particular, refining strategies that mitigate these processes in the vascular smooth muscle compartment but do so in a cell-selective manner is of interest for therapeutic intervention in a variety of vascular pathologies.
See accompanying article on page 2044
Recently, the function of microRNAs (miRNAs) in the setting of vascular disease has gained increasing interest at both the basic science and translational levels. miRNAs, a class of small noncoding RNA, function via binding "seed" sequences of target genes (usually but not exclusively in the 3Ј untranslated region of the target mRNA), resulting in mRNA degradation or repression of translation. A single miRNA can act alone or in concert with others to regulate target genes and physiological and pathophysiological pathways and networks. 1 Understanding their expression profiles, their basic function(s) in complex in vivo environments, and their contribution to disease pathogenesis in both experimental models and clinical samples is of fundamental importance. miRNA expression, regulation, and manipulation in diseases of the cardiac system and in cancer have been explored in great depth, and intervention strategies are being actively developed toward clinical goals. In contrast, the importance and function of miRNA in the peripheral vasculature is relatively less well explored. In the vasculature, a number of miRNAs have been identified and studied in relation to vascular development, physiology, and vascular injury/neointima formation. These miRNAs include the smooth muscle-associated microRNA (miR) 143/145 axis and miR21. [2] [3] [4] miR21 is transcribed from chromosome 17. Expression of mature miR21 is enhanced in a variety of different vascular disease states. For example, in the peripheral arterial system, levels of miR21 are upregulated following acute vascular injury, and inhibition of miR21 via knockdown leads to reduced neointima formation. 5 In the pulmonary vasculature, miR21 is upregulated in vitro via exposure to hypoxia, 6 as well as by vascular smooth muscle cell signaling through transforming growth factor ␤ and bone morphogenetic pro-teins. 7 The latter study elegantly highlighted a mechanistic effect of ligand stimulation of pulmonary vascular smooth muscle cells resulting in enhanced miR21 processing from the primary miR21 transcript by DROSHA. This implies complex regulation of miRNA transcription, and maturation in the vascular smooth muscle compartment in response to pathological stimulation, or both. As such, the function of miR21 in health and disease of the vessel wall is very topical.
In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Wang et al 8 articulate the expression and potential function of miR21 in patients with advanced peripheral arterial disease. Focusing on human tissue and cells, the authors screened 3 normal arteries and 10 with arteriosclerosis obliterans of the lower extremities. Following validation by quantitative polymerase chain reaction, 9 miRNAs remained significantly altered from a total of 617 detected in the normal versus disease screen. In the disease samples, miR21 was upregulated by an average of 8-fold, was localized to the smooth muscle cell compartment (not exclusively, as this miRNA was also localized in other cell types, including fibroblasts), and was greatest in tissue of arteriosclerosis obliterans of the lower extremities with Ͻ10% stenosis. The authors speculate that miR21 may therefore be a marker/mediator of early stenosis in this patient population. Mechanistically, the authors provide evidence to link elevation of mature miR21 expression to the hypoxia inducible factor-1␣ pathway. Furthermore, in a series of in vitro studies, a direct link between miR21 and smooth muscle cell proliferation and migration in response to platelet-derived growth factor-BB (and other stimuli) is documented. Although this observation is not unpredictable, the strength of the current study is in the subsequent identification and validation of tropomyosin 1 (TPM1) as a target gene for miR21 in vascular smooth muscle cells. Tropomyosins are a family of actin-binding proteins that regulate the contractile systems of both smooth and striated muscle and thus have a major role in regulation of the cell shape and cell function. Having validated TPM1 as a target via traditional experimental approaches, the authors report that mRNA levels of TPM1 were not altered via miR21 manipulation despite clear evidence of regulation at the protein level. This is despite a recent report in Nature defining transcript degradation as the predominant (but not exclusive) driver of miRNA function. 9 The authors next overexpressed TPM1, which inhibited vascular smooth muscle cell proliferation and migration, whereas silencing TPM1 blocked the antiproliferative and antimigratory effect of miR21 inhibitors, thereby providing a direct link between miR21, TPM1, and vascular smooth muscle cell phenotype. Functionally, miR21 augmentation enhanced the vascular smooth muscle cell elongation ratio (a surrogate analysis for changes in cell shape quantified by confocal microscopy) and vice versa using miR21 knockdown. An overall summary of the findings is illustrated in the Figure. Collectively, this detailed analysis of miRNA regulation in diseased human peripheral arteries improves our knowledge of miR21 expression patterns in the normal vasculature and in vascular disease in patients; it also further improves our understanding of the impact of miR21 enhancement on specific gene targets and the consequences to the vascular smooth muscle cell. Although the study lacks in vivo interventions to prove the importance of miR21 in pathophysiology, this is offset by the attention to detail in human tissue and intricate and well-performed human cell culture experiments. The impact of increased miR21 on other known (or potential) miR21 targets was not reported. Whether miR21 is a marker or mediator of early stenosis in arteriosclerosis obliterans of the lower extremities remains open to question and further experimentation. With the ability to modulate miRNAs with antagomirs, or anti-miR, manipulating this miRNA in vivo would therefore be an attractive proposition.
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Figure.
A model of microRNA 21 (miR21) regulation of vascular smooth muscle cell phenotype via modulation of tropomyosin 1 (TPM1). Activation of vascular smooth muscle cells via growth factor stimulation, hypoxia, or both leads to elevated levels of mature miR21 in the cell via activation of hypoxia inducible factor-1␣. Elevated miR21 will target a plethora of target genes, either alone or via a concerted action with other miRNAs. One target of miR21 is TPM1, which is downregulated by miR21 at the protein level but not at the mRNA level. TPM1 reduction leads to a reduction in cytoskeletal stability, leading to vascular smooth muscle cell proliferation and migration.
